Eytan M. Stein

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 41 papers. Top paper: “The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia”.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Nature(2023)10.1038/s41586-023-05812-3

N/A

5.2DataRank · unranked

480 citations

Ibrahim Aldoss, John F. Dipersio, Branko Cuglievan, Richard M. Stone, Martha Arellano +19 more

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00494-0

N/A

4.0DataRank · unranked

193 citations

Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton +12 more

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Leukemia(2023)10.1038/s41375-023-02050-4

N/A

0.982DataRank · unranked

52 citations

Maximilian Stahl, Justin Taylor, Xiaoli Mi, Namrata S. Chandhok, Justin M. Watts +11 more

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30209-x

N/A

0.843DataRank · unranked

21 citations

Xiaoli Mi, Alexander Penson, Stella Paffenholz, Kelsey Alvarez, Allison Sigler +10 more

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Blood Advances(2022)10.1182/bloodadvances.2022008625

N/A

0.839DataRank · unranked

19 citations

Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock +35 more

MEN1 mutations mediate clinical resistance to menin inhibition

Nature(2023)10.1038/s41586-023-05755-9

N/A

0.829DataRank · unranked

251 citations

Eytan M. Stein, Daniela V. Wenge, Sukrit Singh, Jeonghyeon Kim, Athina Apazidis +24 more

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Blood Advances(2021)10.1182/bloodadvances.2020003734

N/A

0.787DataRank · unranked

189 citations

Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob L. Glass +14 more

A precision medicine classification for treatment of acute myeloid leukemia in older patients

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01110-5

N/A

0.719DataRank · unranked

15 citations

Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld +15 more

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1966788

N/A

0.574DataRank · unranked

45 citations

Andriy Derkach, Lohith Gowda, Kamal Menghrajani, Susan DeWolf, Josel D. Ruiz +27 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

Nature Communications(2023)10.1038/s41467-023-42585-9

N/A

0.510DataRank · unranked

29 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Leukemia(2025)10.1038/s41375-025-02515-8

N/A

0.396DataRank · unranked

13 citations

Xiaoli Mi, Bin Lü, Andrew Kuykendall, David A. Sallman, Manish R. Patel +16 more

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure

Blood Advances(2025)10.1182/bloodadvances.2025018178

N/A

0.357DataRank · unranked

7 citations

Brian Ball, Yasmin Abaza, Jessica K. Altman, Rahul Thakur, Moiez Ali +12 more

Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial

Therapeutic Innovation & Regulatory Science(2021)10.1007/s43441-021-00277-w

N/A

0.353DataRank · unranked

5 citations

Hugh Levaux, Ross L. Levine, Amit Shah, James Denmark, Nyla Hereema +18 more

Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies

Haematologica(2024)10.3324/haematol.2024.285054

N/A

0.345DataRank · unranked

9 citations

Kseniya Petrova‐Drus, Ryan Ptashkin, Mark D. Ewalt, JinJuan Yao, Ying Liu +43 more

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies

British Journal of Haematology(2024)10.1111/bjh.19826

N/A

0.261DataRank · unranked

4 citations

Jeetayu Biswas, Omar Abdel-Wahab, Eytan M. Stein, Leora Boussi

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01724-z

N/A

0.254DataRank · unranked

4 citations

Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam +11 more

Acute myeloid leukemia with mixed phenotype is characterized by RUNX1 mutations, stemness features and limited lineage plasticity

medRxiv(2023)10.1101/2023.11.01.23297696

N/A

0.208DataRank · unranked

3 citations

Deepika Dilip, Andriy Derkach, Alexander Chan, Yanming Zhang, Sonali Persuad +14 more

HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML

Leukemia & lymphoma/Leukemia and lymphoma(2024)10.1080/10428194.2024.2411436

N/A

0.165DataRank · unranked

2 citations

Andriy Derkach, Christopher Famulare, Gaurav K. Gupta, P. Dayand Borge, Mark B. Geyer +8 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing

medRxiv(2022)10.1101/2022.10.03.22280675

N/A

0.130DataRank · unranked

1 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs

Cancer(2025)10.1002/cncr.70024

N/A

0DataRank · unranked

3 citations

Leora Boussi, David Nemirovsky, Andriy Derkach, Jenna Ciervo, Christopher Famulare +12 more

Venetoclax in Combination With Pediatric‐Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial

American Journal of Hematology(2025)10.1002/ajh.70082

N/A

0DataRank · unranked

1 citations

David Nemirovsky, Andriy Derkach, I. Cacace, Martina Torres, Colleen Finneran +6 more

Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors

Blood Cancer Journal(2025)10.1038/s41408-026-01545-4

N/A

0DataRank · unranked

0 citations

Karmelina Charalambous, Shanita Li, Kaitlyn Ko, H. Casanova, Cassidy C. Cobbs +9 more

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Blood Advances(2023)10.1182/bloodadvances.2023009675

N/A

0DataRank · unranked

19 citations

David Nemirovsky, Christopher Famulare, Noushin Farnoud, Abhinita Mohanty, Zoe S. Stone-Molloy +22 more

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

Leukemia Research Reports(2020)10.1016/j.lrr.2020.100211

N/A

0DataRank · unranked

8 citations

Zoe McKinnell, Jae H. Park, Eytan M. Stein, Sheng F. Cai, Justin Taylor +1 more

Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.11.089060

N/A

0DataRank · unranked

7 citations

S. Haihua Chu, Aaron D. Goldberg, Salma Parvin, Richard P. Koche, Jacob L. Glass +22 more

Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.05.011

N/A

0DataRank · unranked

41 citations

Stephanie Lobaugh, Josel D. Ruiz, Parastoo B. Dahi, Aaron D. Goldberg, James W. Young +22 more

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

American Journal of Hematology(2021)10.1002/ajh.26146

N/A

0DataRank · unranked

16 citations

Meier Hsu, Sean M. Devlin, Maria E. Arcila, Mikhail Roshal, Yanming Zhang +17 more

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

American Journal of Hematology(2022)10.1002/ajh.26757

N/A

0DataRank · unranked

25 citations

Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy M. Robinson, Christopher Famulare +35 more

Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia

Leukemia Research(2022)10.1016/j.leukres.2022.106970

N/A

0DataRank · unranked

8 citations

Emily A. Cowen, Joseph R. Stoll, Haoling Zhu, Stephen W. Dusza, Melissa Pulitzer +3 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing

Research Square(2022)10.21203/rs.3.rs-2094202/v1

N/A

0DataRank · unranked

0 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

medRxiv(2022)10.1101/2022.12.26.22283876

N/A

0DataRank · unranked

0 citations

David Nemirovsky, Christopher Famulare, Noushin Farnoud, Abhinita Mohanty, Zoe S. Stone-Molloy +22 more

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

The Lancet Haematology(2020)10.1016/s2352-3026(20)30205-2

N/A

0DataRank · unranked

97 citations

Prajwal Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal +47 more

A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC

Journal of Hematology & Oncology(2024)10.1186/s13045-024-01571-4

N/A

0DataRank · unranked

35 citations

Valentina Nardi, Eytan M. Stein, Robert P. Hasserjian, Wenbin Xiao

Aberrant pre-mRNA processing in cancer

The Journal of Experimental Medicine(2024)10.1084/jem.20230891

N/A

0DataRank · unranked

8 citations

Leora Boussi, Eytan M. Stein, Omar Abdel-Wahab, Jeetayu Biswas

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Blood Advances(2024)10.1182/bloodadvances.2024012858

N/A

0DataRank · unranked

12 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

American Journal of Hematology(2024)10.1002/ajh.27366

N/A

0DataRank · unranked

9 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

Blood Neoplasia(2024)10.1016/j.bneo.2024.100038

N/A

0DataRank · unranked

3 citations

Yannis K. Valtis, Andriy Derkach, Meira Yisraeli Salman, Leora Boussi, Jenna Ciervo +7 more

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML

Research Square(2024)10.21203/rs.3.rs-4954060/v1

N/A

0DataRank · unranked

0 citations

Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam +11 more

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

Cell stem cell(2025)10.1016/j.stem.2025.04.012

N/A

0DataRank · unranked

19 citations

Soobeom Lee, Zhengxi Sun, Ronan Chaligné, Sanam Loghavi, Georgios Asimomitis +30 more

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3790

N/A

0DataRank · unranked

11 citations

Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás‐Cardama, Sarah A. Reilly +25 more

Advances in menin inhibition in acute myeloid leukemia

Trends in cancer(2025)10.1016/j.trecan.2025.06.002

N/A

0DataRank · unranked

6 citations

Sheng F. Cai, Eytan M. Stein, Leora Boussi